Souraka Tapara Dramani Maman, Shi Ming-Jun, Meng Xiang-Yu
Département de Diagnostic Génétique, Hôpital Zhongnan de l'Université de Wuhan, 169 Rue Donghu, Wuchang, Wuhan 430071, Chine.
Institut Curie, PSL Research University, CNRS, UMR 144, F-75005, Paris, France.
Pan Afr Med J. 2017 Aug 10;27:270. doi: 10.11604/pamj.2017.27.270.12282. eCollection 2017.
Previous studies about the relationship between tumor recurrence and NRAMP1 and HGPX1 gene polymorphism in patients with non-muscle-invasive bladder cancer (NMIBC) showed inconsistent results.
We conducted a systematic review of the literature on the basis of data from PubMed and China National Knowledge Infrastructure. According to the predefined selection criteria, the eligibility criteria for the studies found in the literature were assessed by two independent authors. The basic characteristics of the included studies and of data relevant to the meta-analysis were extracted. Patients? survival without recurrence was selected as the measure of effect of meta-analysis.
Four publications were retained. Three studies evaluated the NRAMP1 D534N and three the hGPX1 Pro168Leu. Depending on the association between NRAMP1 D534N and tumor recurrence, the meta-analysis revealed no significant heterogeneity and the combined effect was 3.28 [1.77, 6.11]. Depending on the association between hGPX1 Pro198Leu and tumor recurrence, the meta-analysis showed significant heterogeneity and the combined effect was 1.12 [0.45, 2.77]. Publication bias was uncertain, due to the limited number of included studies.The instability of the combined effects was reported.
Very little data are available on the association between tumor recurrence and NRAMP1 D534N and hGPX1 Pro168Leu poolymorphisms in patients with NMIBC. The NRAMP1 D534N could increase the risk of recurrence, but hGPX1 Pro168Leu effect is not clear. A more thorough investigation should be conducted on a larger sample size in order to better explain this phenomenon.
先前关于非肌层浸润性膀胱癌（NMIBC）患者肿瘤复发与NRAMP1和HGPX1基因多态性之间关系的研究结果并不一致。
我们基于来自PubMed和中国知网的数据对文献进行了系统回顾。根据预先设定的选择标准，由两位独立作者评估文献中所发现研究的纳入标准。提取纳入研究的基本特征以及与荟萃分析相关的数据。选择患者无复发存活情况作为荟萃分析的效应量指标。
保留了4篇出版物。3项研究评估了NRAMP1 D534N，3项研究评估了hGPX1 Pro168Leu。根据NRAMP1 D534N与肿瘤复发之间的关联，荟萃分析显示无显著异质性，合并效应为3.28 [1.77, 6.11]。根据hGPX1 Pro198Leu与肿瘤复发之间的关联，荟萃分析显示存在显著异质性，合并效应为1.12 [0.45, 2.77]。由于纳入研究数量有限，发表偏倚情况不确定。报告了合并效应的不稳定性。
关于NMIBC患者肿瘤复发与NRAMP1 D534N和hGPX1 Pro168Leu多态性之间关联的数据非常少。NRAMP1 D534N可能会增加复发风险，但hGPX1 Pro168Leu的作用尚不清楚。应为了更好地解释这一现象，在更大样本量上进行更深入的研究。
